NA
HARP

NewEdge Advisors’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

NewEdge Advisors’s Portfolio HARP Stock Details HARP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-12
Closed -$83 – 4294
2022
Q4 		$83 Buy
+12
New +$101 ﹤0.01% 3398

Other funds holding HARP

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

NewEdge Advisors's HARP Position: Q1 2023 in Review

NewEdge Advisors sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q1 2023, closing a stake of 12 shares — an estimated $83 sold.

NewEdge Advisors first reported a position in HARP in Q4 2022 and held it in 1 quarter. The position peaked at $83 in Q4 2022. 46 funds tracked by Wall St. Rank hold HARP as of Q1 2023.

  • NewEdge Advisors reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • NewEdge Advisors sold 12 Harpoon Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $83.
  • NewEdge Advisors first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • NewEdge Advisors's Harpoon Therapeutics, Inc. Common Stock position peaked at $83 in Q4 2022.
  • 46 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q1 2023.

Based on NewEdge Advisors's 13F filing for Q1 2023, filed 12 May 2023.